An international team of researchers has now comprehensively profiled and categorised over 700 tumour samples from patients with chronic lymphocytic leukaemia (CLL) by analysing multiple levels of encoded biologic information.
Through detailed mapping of the derived information, they identified major biologic categories associated with distinct modes of resistance to different treatment combinations.
Besides changes indicating heterogeneous levels of inflammatory activity, the degree of genomic instability turned out to be a major discriminatory feature for the tumour subgroups.
In cancer biology, high levels of genomic instability increase the likelihood for alterations in the genome and largely depend on the tumours capabilities to recognise and repair acquired DNA-damage.
Genomic instability in CLL has been linked to mutations or chromosomal losses of regions encoding the cellular watchers for genome protection, the so-called tumour suppressor genes.
Tumours exhibiting inactivation of tumour suppressor genes usually have a poor outcome and early detection helps to choose the most appropriate treatments. However, genomic instability also occurs in many CLL cases without such detectable alterations.
As reported by Johannes Bloehdorn and colleagues in Nature Communications, tumour sample analysis included the assessment of gene mutations, chromosomal aberrations, DNA-methylation, gene and protein expression, and associated pathway-signalling activity.
The authors were able to decode the tumour biology and translate the underlying information in a way that makes it possible to categorise tumours irrespective of detectable losses or mutations of tumour suppressor or DNA-repair genes.
The authors further discovered that genomically instable tumours do not just shut down DNA repair but show boosted and highly error-prone repair activity. This further increases accumulation rates of genomic alterations, accelerating the development of resistance.
Another major subgroup identified in this study, showing the lowest degree of genomic instability, exhibits characteristics observed during the process of metastasis in solid tumours, which were previously not known to build subgroup-specific functional networks in CLL.
CLL cells can reach any part of the body via the bloodstream. Therefore, it appears redundant to develop mechanisms that enable the cell to break free from a tumour to search for a better survival niche, which is represented through the process of metastasis in solid tumours.
However, these uncovered networks may increase the ability for leukaemia cells to exit the bloodstream and migrate to lymphoid tissues. Several targeted treatment approaches address related mechanisms and the cells ability to accumulate in lymphoid organs.
The now established tumour classification represent a significant advance in understanding the underlying biology, mechanisms of resistance and ultimately may improve prognostic models for personalised treatment approaches in CLL, and possibly other tumour entities.
